Swedish Orphan Biovitrum AB (publ) (LON:0MTD)

Market Cap	8.99B
Revenue (ttm)	2.20B
Net Income (ttm)	1.03M
Shares Out	n/a
EPS (ttm)	0.00
PE Ratio	8,760.71
Forward PE	17.52
Dividend	n/a
Ex-Dividend Date	n/a

Volume	30,802
Average Volume	146,845
Open	319.50
Previous Close	318.00
Day's Range	315.80 - 329.60
52-Week Range	242.60 - 347.20
Beta	0.19
RSI	45.88
Earnings Date	Feb 5, 2026

About LON:0MTD

Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocy...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1939
• Employees: 1,806
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0MTD

Financial Performance

In 2024, LON:0MTD's revenue was 26.03 billion, an increase of 17.65% compared to the previous year's 22.12 billion. Earnings were 3.89 billion, an increase of 61.27%.

Financial numbers in SEK